Latest Healthcare News

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

Universal Biosensors reports a $1.59 million improvement in operating cash outflows for Q2 2025, maintaining $2.55 million in cash as it advances commercialization across blood, wine, and water testing markets.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.

Audeara Ltd has reported a landmark FY25 with record cash receipts of $4.9 million, driven by strong domestic sales and expanding global technology partnerships. The company’s strategic R&D and inventory build set the stage for further growth in FY26.

Regis Healthcare has agreed to acquire four premium aged care homes in South-East Queensland from Rockpool, adding 600 beds and boosting its portfolio to 72 homes. The $135 million deal is expected to be earnings accretive in FY26.

Regis Healthcare has agreed to acquire four premium aged care homes in South-East Queensland from Rockpool RAC Holdings, adding 600 beds to its portfolio. The $135 million deal, funded from existing cash reserves, is expected to complete by September 1, 2025.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Integral Diagnostics has been served with a legal claim from vendors disputing the earn out valuation of its Imaging Queensland acquisition, despite an independent expert's prior valuation. The company plans to defend the claim, which could have financial and reputational implications.

Austco Healthcare reports robust FY25 growth with revenue climbing over 37% and EBITDA soaring by more than 54%, fueled by strong organic performance and key acquisitions.